A PHASE I STUDY OF VEGF- ANTISENSE OLIGONUCLEOTIDE (VEGF-AS) GIVEN AS A DAILY

每日给予 VEGF 反义寡核苷酸 (VEGF-AS) 的 I 期研究

• 批准号: 7603936
• 负责人: ALEXANDRA M LEVINE
• 金额: $ 3.59万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603936
• 关键词: Antisense Oligonucleotides; Computer Retrieval of Information on Scientific Projects Database; Daily; Dose; Funding; Grant; Institution; Malignant Neoplasms; Patients; Phase; Phase I Clinical Trials; Refractory; Relapse; Research; Research Personnel; Resources; Source; Subcutaneous Injections; United States National Institutes of Health; Vascular Endothelial Growth Factors

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A Phase I study of VEGF-Antisense Oligonucleotide (VEGF-AS) given as a daily fixed dose subcutaneous injection in the treatment of patients with relapsed or refractory malignancies.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 每日固定剂量皮下注射血管内皮生长因子反义寡核苷酸治疗复发或难治性恶性肿瘤的I期研究。